All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

American Society of Clinical Oncology Recognizes Dr Neeraj Agarwal

April 4th 2023

Neeraj Agarwal, MD, is now a distinguished member of the Fellows of the American Society of Clinical Oncology.

Dr. Sadai on Signs and Symptoms of High-Grade Meningiomas

April 4th 2023

Nader Sanai, MD, discusses symptoms associated with high-grade meningiomas, a rare brain tumor.

Dr. Brastianos on Recent Data in High-Grade Meningiomas

April 4th 2023

Priscilla K. Brastianos, MD, reviews recent findings in high-grade meningiomas, including data generated in her laboratory.

TAVO-EP Plus Pembrolizumab Fails to Meet ORR End Point in Anti–PD-1–Refractory Advanced Melanoma

April 4th 2023

The combination of the interleukin-12 encoding plasmid TAVO™-EP plus pembrolizumab did not meet the prespecified primary end point for overall response rate in patients with advanced melanoma that was refractory to anti–PD-1 therapy.

FDA Accepts sNDAs for Encorafenib and Binimetinib in BRAF V600E–Mutant NSCLC

April 4th 2023

The FDA has accepted for review supplemental new drug applications for the combination of encorafenib and binimetinib for the treatment of patients with metastatic non–small cell lung cancer harboring a BRAF V600E mutation, as detected by an FDA-approved test.

Imetelstat Displays Early Efficacy in Myelofibrosis; Phase 3 Trial Is Underway

April 4th 2023

The first-in-class telomerase inhibitor imetelstat is poised to expand the myelofibrosis treatment armamentarium should it prove safe and effective in the newly initiated phase 3 IMpactMF trial.

Teclistamab Leads Ongoing Emergence of Bispecific Antibodies in Multiple Myeloma

April 4th 2023

Jeffrey Zonder, MD, discussed the ongoing development of other BCMA-targeted and non–BCMA targeted bispecific antibodies, toxicity management for these agents, how to navigate treatment decisions for patients eligible for CAR T-cell therapy, and ongoing research in multiple myeloma at the Barbara Ann Karmanos Cancer Institute.

FDA Approves Enfortumab Vedotin Plus Pembrolizumab for Locally Advanced or Metastatic Urothelial Carcinoma

April 3rd 2023

The FDA has granted accelerated approval to enfortumab vedotin-ejfv (Padcev) plus pembrolizumab (Keytruda) for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin-containing chemotherapy.

Quizartinib May Represent an Additional Therapeutic Option for FLT3-ITD+ AML

April 3rd 2023

Mark Levis, MD, PhD, discusses potential changes to the FLT3-ITD-mutated acute myeloid leukemia treatment landscape that may occur if the FDA approves quizartinib, key efficacy and safety data with the agent, and how quizartinib compares with midostaurin.

Tamibarotene Combinations Under Investigation in Newly Diagnosed AML and MDS

April 3rd 2023

Gautam Borthakur, MD, discussed the rationale for targeting RARA-overexpressing AML, the potential efficacy and safety benefits of tamibarotene, and how SELECT AML-1 and SELECT MDS-1 could change the respective treatment landscapes in AML and MDS.

Eftilagimod Alpha/Pembrolizumab Generates Antitumor Activity in PD-1–Resistant NSCLC

April 3rd 2023

Treatment with eftilagimod alpha plus pembrolizumab resulted in tumor shrinkage and a tolerable safety profile in patients with anti–PD-1/PD-L1–resistant non–small cell lung cancer.

$3.2 Million Grant Supports Study of New Genetic Testing Approach to Reduce Racial Health Disparities

April 3rd 2023

With a National Cancer Institute grant, investigators from Rutgers Cancer Institute of New Jersey and Georgetown University’s Lombardi Comprehensive Cancer Center will work to close racial disparity gaps in cancer care delivery by examining a novel approach to genetic testing and care based on community identified needs.

Sodium Thiosulfate Receives Recommendation for European Approval for Cisplatin-Induced Ototoxicity in Pediatric Patients

April 3rd 2023

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of sodium thiosulfate injection for the prevention of ototoxicity induced by cisplatin chemotherapy in patients 1 month to less than 18 years of age with localized, nonmetastatic solid tumors.

Rusfertide Improves Responses, Meets Primary End Point of REVIVE Trial in Polycythemia Vera

April 3rd 2023

Treatment with rusfertide led to a higher response rate of 69.2% vs 18.5% with placebo in patients with polycythemia vera, meeting the primary end point of the phase 2 REVIVE trial.

Cytokines Play Integral Role in Cancer Immune Cycle

April 3rd 2023

In the setting of cancer, cytokines contribute to cells’ antitumor response, cell damage, inflammation, angiogenesis, metastasis, and other cellular processes that enable tumor survival

Applied Molecular Medicine Signals the Future of Personalized, Preventive Cancer Care

April 3rd 2023

Andre Goy, MD, discusses advances in the field of oncology that prompted the development of the Hennessy Institute, how early cancer detection can improve patient outcomes, and the importance of employing accessible cancer prevention strategies.

Atezolizumab/Cabozantinib Fails to Elicit Benefit Over SOC in Second-line Metastatic NSCLC

April 2nd 2023

Second-line atezolizumab plus cabozantinib did not generate a clinical benefit over standard-of-care docetaxel in patients with metastatic non–small cell lung cancer previously treated with immune checkpoint inhibitors and chemotherapy.

Teclistamab, Other BCMA-Targeted Agents Represent New Options in Relapsed/Refractory Myeloma

April 1st 2023

Andrew Kin, MD, expands on the ways BCMA-targeted therapies that are currently available and under development have shifted the treatment landscape for relapsed/refractory multiple myeloma, the implications of the approval of teclistamab, and the limitations that still exist for using BCMA-targeted agents.

Tusamitamab Ravtansine Plus Pembrolizumab With or Without Chemo Elicits Responses in CEACAM5+ NSCLC

April 1st 2023

The combination of tusamitamab ravtansine and pembrolizumab with or without chemotherapy generated responses and was well tolerated when used as first-line treatment for patients with CEACAM5-positive nonsquamous non–small cell lung cancer.

Cemiplimab Monotherapy Induces Durable OS, PFS Benefits in PD-L1+ NSCLC With Brain Metastases

March 31st 2023

Frontline cemiplimab plus chemotherapy improved overall survival and progression-free survival compared with investigator’s choice of chemotherapy for patients with PD-L1–positive non–small cell lung cancer that has metastasized to the brain.